IRVINE, Calif., June 23 /PRNewswire/ -- Relsys International, the leading provider of drug safety, pharmacovigilance and risk management solutions for the pharmaceutical industry, announces that Mr. Bruce Palsulich has joined the company as Chief Innovation & Strategy Officer, reporting directly to the CEO. In this role, he will oversee Relsys' future product development and direction, and drive corporate strategic initiatives.

Mr. Palsulich is one of Relsys' original employees, having been with the company since inception. He was formerly Vice President of Product Development at Relsys, departing in 2004 to pursue personal entrepreneurial initiatives. At the time, he was responsible for customer requirements, product direction and business development. Mr. Palsulich is also the original developer of the Argus Safety(TM) suite. He brings with him extensive knowledge and understanding of the pharmaceutical industry, particularly in risk management.

Mr. Dave Bajaj, President & CEO of Relsys, commented, "We welcome Bruce back to the Relsys organization. His return has been very well received by clients who have worked with him in the past. His broad, in-depth understanding of and exposure to global pharmacovigilance business practices will provide the backbone of our future product direction." Mr. Palsulich added, "Relsys has demonstrated unparalleled growth, rapidly gaining the largest user base of any drug safety system in the world. I look forward to working closely with this large client pool to continue to expand Relsys' risk management leadership."

About Relsys International

Relsys International provides the industry-leading Argus suite, a complete systems solution for drug safety, pharmacovigilance and risk management that helps pharmaceutical, biotech and medical device companies improve drug safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety(TM), the company's flagship product, is the world's best selling drug safety and adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit http://www.relsys.net, or call +1 949-453-1715.

CONTACT: Relsys International, +1-949-453-1715

Web site: http://www.relsys.net/